Moderna Clinical Trials Terribly Flawed, and FDA Knew It, Former Pharma Executive Tells

Moderna Clinical Trials Terribly Flawed, and FDA Knew It, Former Pharma Executive Tells Robert F. Kennedy, Jr.

August 9, 2022

There were "terrible flaws" in Moderna's COVID-19 vaccine clinical trials — and the U.S. Food and Drug Administration knew it, Alexandra (Sasha) Latypova told Robert F. Kennedy, Jr., on a recent episode of "RFK Jr. The Defender Podcast."

There were "terrible flaws" in Moderna's COVID-19 vaccine clinical trials — and the U.S. Food and Drug Administration (FDA) knew it, according to Alexandra Latypova, a former pharmaceutical industry executive who reviewed nearly 700 pages of documents Moderna submitted to the FDA as part of its application process.

Latypova, who has 25 years of experience in pharmaceutical research and development, started a number of successful companies — primarily focused on creating and reviewing clinical trials.

On a recent episode of "RFK Jr. The Defender Podcast," she told Kennedy what she learned after reviewing the Moderna documents, obtained via a Freedom of Information Act request.

Latypova told Kennedy that out of nearly 700 pages, about 400 pages are irrelevant studies that Moderna repeated multiple times.

Moderna also submitted three versions of a single module, she said. And one module contained only narrative summaries of Moderna's studies, but no actual study results.

"So we are still missing a large number of results, such as full reports that are supporting those narratives," Latypova told Kennedy.

The FDA "obviously did not object" to any of this, she said. "That's evidence of collusion to me with the manufacturer."

Latypova also discussed Moderna's clinical trials timeline. She said the Investigational New Drug (IND) application meeting is supposed to occur with the FDA when the company initiates human clinical trials.

Moderna and the FDA had a pre-IND meeting on Feb. 19, 2020, and the IND application was formally opened the next day. The global pandemic was declared on March 11, 2020.

"Somehow these visionaries could predict the future with such certainty that they opened a clinical trial for the vaccine, for which a pandemic was announced a month later," Latypova said.

There is normally only one IND application for one product. In this case, however, there are two IND applications — one belonging to Moderna, and one belonging to the National Institutes of Health, which partnered with Moderna on its COVID-19 vaccine.

Latypova also told Kennedy that Moderna did not conduct studies to determine if its mRNA vaccine affected male fertility.

"We have no idea what [the vaccine] does to young men who want to have children in the future," she said.

The documents also confirm that Moderna's trials studied the vaccine's delivery mechanism, but not its payload, which in this case is the spike protein.

"They want you to believe that … you can … have a truck filled with food, or you can have a truck filled with explosives," Latypova said. "They're saying it doesn't matter. Focus on the truck. It's the same truck, doesn't matter what's inside."

In the end, Latypova said, "They're desperate to vaccinate every single person on the planet because they don't want you to know what's going on."

https://childrenshealthdefense.org/defender/moderna-clinical-trials-flawed-fda-pharma-executive-alexandra-latypova-rfk-jr-podcast/